Medication in Alzheimer's disease;Les médicaments face à la maladie d'Alzheimer

Revue de Geriatrie

Volumn 26, Issue 6, 2001, Pages 511-522

  Bentue Ferrer D ^a   Michel, B F ^a   Reymann, J M ^a   Allain, H ^a  

^a Institute de Chimie de'Rennes   (France)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Pharmacology; Pharmacovigilance; Therapeutics

Indexed keywords

ANTIOXIDANT; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN DERIVATIVE; GALANTAMINE; MEMANTINE; METRIFONATE; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT; PROPENTOFYLLINE; PSYCHOTROPIC AGENT; RIVASTIGMINE; SABELUZOLE; TACRINE; VIVIQ; XANOMELINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG RESEARCH; HUMAN; PRESCRIPTION; PUBLICATION;

EID: 0034946663     PISSN: 03977927     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Experimental and clinical methods in the development of anti-Alzheimer drags
2. Le choix des théapeutiques dans la maladie d'Alzheimer
3. Traitements médicamemeux des démences
4. Treatment of Alzheimer's disease: Current approaches and promising developments
5. Treatment of Alzheimer's disease
6. Cholinesterase inhibitors: A new class of psychotropic compounds
7. Evidence for psychotropic effects of acetylcholinesterase inhibitors
8. Oral tetrahydroaminoacridine in long-term treatment of senile dementia Alzheimer type
9. Cholinesterase inhibitors in Alzheimer's disease. Are they worth the cost?
10. Tacrine in Alzheimer's disease
11. A controlled trial of tacrine in Alzheimer's disease
12. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
13. A double-blind, placebo-controlled, enriched population study on tacrine in patients with Alzheimer's disease
14. A double blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease
15. A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: Methodologic considerations
16. Hepatotoxicity due to tacrine
17. Pharmacoepiderniology of tacrine in Alzheimer's disease
18. Donepezil (Aricep®): Inhibiteur de l'acétyl cholinestérase et maladie d'Alzheimer
19. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double blind, placebo-controlled trial
20. A 24-week, double blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
21. The effects of donepezil in Alzheimer's disease- results from a multinational trial
22. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: A final analysis of a US multicentre open-label study
23. Donepezil in Alzheimer's disease: Relative cognitive and neuropsychiatric responses and impact on caregiver distress
24. Donepezil therapy in clinical practice: A randomized cross over study
25. Guidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer's disease
26. Rivastigmine: A review of its use in Alzheimer's disease
27. Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease
28. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetytcholinesterase inhibitor in patients with mild to moderately severe Alzheimer's disease
29. Efficacy and safety of rivastigrnine in patients with Alzheimer's disease: International randomised controlled trial
30. Effets indésirables et médicaments de la maladie d'Alzheimer
31. Aminotransferases levels and silymarine in de novo tacrine treated patients with Alzheimer's disease
32. New drug treatment for Alzheimer's disease: Lessons for healthcare policy
33. Effectiveness of rivastigmine in Alzheimer's disease
34. Galanthamine
35. Galantamine in AD. A 6-month randomized, placebo-controlled trial with 6-month extension
36. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B
37. Propentofylline
38. Clinical trials in dementia with propentofylline
39. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: A review of phase III trials
40. Metrifonate
41. Metrifonate: A new agent for the treatment of Alzheimer's disease
42. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease
43. Metrifonate treatment of the cognitive deficits of Alzheimer's disease
44. Beyond the cholinergic hypothesis: The effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease
45. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
46. Xanomeline: A novel muscarinic receptor agonist with functional selectivity for M1 receptors
47. Neurochemical effects of the M1 muscarinic agonist xanomeline (LY 246708/NNC 11-0232)
48. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease
49. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease
50. Non steroidal antinflammatory drugs and Alzheimer's disease. Update on recent data and their therapeutic implications
51. Risk of Alzheimer's disease and duration of NSAID use
52. Oestrogènes et maladie d'Alzheimer
53. The role of oxidative stress in Alzheimer disease
54. Free radicals in Alzheimer's dementia: Currently available therapeutic strategies
55. Alzheimer's disease and oxidative stress: Implications for novel therapeutic approaches
56. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
57. L-deprenyl in Alzheimer's disease. Cognitive and behavioral effects
58. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia
59. The efficacy of Ginkgo biloba on cognitive function in Alzheimer's disease
60. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease
61. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease
62. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: A Nordic multicentre study
63. Moclobemide in elderly patients with cognitive decline and depression: An international double-blind placebo-controlled trial
64. Monoamine oxidase inhibitors, cognitive functions and neurodegenerative disease
65. Depression and Parkinson's disease
66. Anxiolytics in the treatment of BPSD
67. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
68. Double blind study of tiapride versus halopetidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment
69. General safety profile of zolpidem: Safety in elderly overdose and rebound effects
70. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease
71. Huperzine A
72. Development of nicotinic drug therapy for cognitive disorders
73. Allosteric modulation of nicotinic acetylchotine receptors as a treatment strategy for Alzheimer's disease
74. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: Update on a 2 year double-blind multicentre study
75. Perspectives in clinical Alzheimer's disease research and the development of antidementia drugs
76. Recent developments in the drug treatment of Alzheimer's disease
77. Prospects for pharmacological intervention in Alzheimer disease
78. Scientists raise possibility of vaccine for Alzheimer's disease
79. Théapie multiconceptuelle dans la maladie d'Alzheimer
80. A unifying hypothesis of Alzheimer's disease. 1 Ageing sets the stage
81. Pharmacology and clinical efficacy of cholinesterase inhibitors
82. Cholinesterase inhibitors in the treatment of Alzheimer's disease. A comparison of tolerability and pharmacology
83. La maladie d'Alzheimer
84. Alzheimer's disease - A metallic problem
85. A double blind, placebo-controlled, multicenter study of cerebolysin for Alzheimer's disease